Navigation Links
WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
Date:10/26/2007

SHANGHAI, China, Oct. 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that it has been ranked the 28th in the Deloitte Technology Fast 50 China program, a ranking of the 50 fastest growing technology companies in China. The awards ceremony was held in the JW Marriott Hotel Shanghai at Tomorrow Square, Shanghai on October 25.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The Deloitte Technology Fast 50 China program ranks leading companies in Technology, Media and Telecom (TMT) sectors based on their average revenue growth rates over the last three years. Given China's rapid economic growth, the strong development of the TMT industry, the government advocating technology innovation and the appetite of local and overseas venture capital for fast growing technology companies, this year's revenue growth requirement for winning has substantially increased. As a result, more than half of the winners are the first time winners and only one of the top 10 winners is a previous winner.

Ranked the 22nd, 27th and 28th in 2005, 2006 and 2007, respectively, WuXi PharmaTech is one of the nine companies to win the award for three consecutive years.

''We are pleased to be recognized by Deloitte for our accomplishments for the third time," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "As the whole industry sector enjoys remarkable growth, WuXi PharmaTech has grown from a small start-up to a New York Stock Exchange listed company. I am very proud that we still can maintain our relative rank on the list, and I would like to take this opportunity to thank our customers for their strong support and employees for their dedication and hard work," continued Dr. Li.

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, toxicology, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com.

For more information, please contact:

Sherry Shao

Tel: +86 (21) 5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UW-Madison MBA program ranked among best for investment return
2. Madison top-ranked In Digital Cities Survey
3. Oshkoshs Pierce Security Vehicle Ranked in top 100 Technological Innovations for 2003
4. Wisconsin Companies Ranked Top in Nation in IT
5. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
6. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
7. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
8. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
9. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
10. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
11. Use of Novel FlashPlate Technology to Measure cAMP Accumulation in Chinese Hamster Ovary Cells Expressing Human -2 Adrenoreceptors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... AESKU.GROUP, ... DST Diagnostische Systeme & Technologien GmbH, thereby expanding its product portfolio to include ... hay fever, urticaria, asthma, atopic eczema or a food allergy. Allergies are escalating ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... release of Limfinity® version 6.5, a content-packed update to the Limfinity® framework. , ... a larger and more diverse base of customers among labs and other businesses. ...
(Date:6/20/2017)...  Kibow Biotech Inc., a pioneer in developing "Enteric ... a new patent covering a unique method for preventing ... and Trademark Office on May 23 rd 2017. ... Bio award in 2014 in San Diego, ... to chronic disease. Renadyl™, the first and only dietary ...
(Date:6/19/2017)... ... June 19, 2017 , ... EDETEK, Inc., a clinical technology ... is launching two new additions of its award-winning cloud-based platform CONFORM™: Information Hub ... DIA 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. , “Modern clinical ...
Breaking Biology Technology:
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):